Table.

Summary of included studies.

Study ID	Setting	Country	Total randomized (n)	Mean age (years)	Intervention	Control	Primary outcome
Martin 1993	Single center, ICU	France	32	52.5	Norepinephrine (0.5 mcg/kg/min)	Norepinephrine (0.5 mcg/kg/min)	Systemic and regional haemodynamic achievement
Annane 2007	Multi-center, 19 ICU	France	330	63	Norepinephrine (0·2 mcg/kg/min min) ± dobutamine (5 mcg/kg/min)	Epinephrine (0·2 mcg/kg/min) ± placebo	28-day all-cause mortality
Morelli 2008	Single center, ICU	Italy	32	70	Norepinephrine	Phenylephrine	Study drugs requirement, systemic and regional haemodynamic achievement
Myburgh 2008	Multi-center, 4 ICU	Australia	280	59.9	Norepinephrine	Epinephrine	Achievement of MAP goal >24 h without vasopressors
Russell 2008	Multi-center, 27 centers	Canada, Australia, and USA	778	60.5	Norepinephrine (5 to 15 mcg/min)	Vasopressin (0.01 to 0.03 U/min)	28-day mortality of any cause
De Backer 2010	Multi-center, 8 ICU	Belgium, Austria, and Spain	1,679	67.5	Norepinephrine	Dopamine	Rate of death at 28 days
Patel 2010	Single center, ICU	USA	252	Not stated	Norepinephrine (maximum of 20 mcg/min)	Dopamine (maximum of 20 mcg/kg/min)	28-day all-cause mortality
Choudhury 2016	Single center, ICU	India	84	47.5	Norepinephrine (7.5 mcg/min to 60 mcg/min)	Terlipressin (1.3 to 5.2 mcg/min)	Achievement of MAP of >65 mm Hg and maintenance of the same for the initial 48 hours
Gordon 2016	Multi-center, 18 ICU	United Kingdom	409	66	Norepinephrine (maximum of 12mcg/min)	Vasopressin (maximum of 0.06 U/min)	Kidney failure-free days during the 28 days after randomization
Liu 2018	Multi-center, 21 ICU	China	617	61	Norepinephrine (4 to 30mcg/min)	Terlipressin (20 to 160 mcg/h)	28-day all-cause mortality
Permpikul 2019	Single-center, ED	Thailand	310	Not stated	Norepinephrine (0.05 mcg/kg/min)	Placebo (Dextrose 5% in water)	Shock control rate by 6 hours

ICU, intensive care unit; mcg, microgram; kg, kilogram; min, minute; U, unit; h, hour; MAP, mean arterial pressure; ED, emergency department.